Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CIT | O14578 | 11/20 | 0.60 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
| ▸ | IKBKB | O14920 | 3/20 | 0.52 |
| ▸ | CHUK | O15111 | 3/20 | 0.52 |
| ▸ | KIT | P10721 | 3/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30008811 | 0.87 | CIT (0.60) | CITIKBKBCHUKJAK1 | |
| SCHEMBL30008778 | 0.87 | CIT (0.61) | CITIKBKBCHUKJAK1 | |
| SCHEMBL30009181 | 0.84 | CIT (0.50) | CITNUDT1IKBKBCHUKPGR | |
| SCHEMBL30009247 | 0.83 | CIT (0.62) | CITIKBKBCHUKPGRJAK1 | |
| SCHEMBL29548773 | 0.82 | BRD4 (0.64) | — | |
| SCHEMBL28723192 | 0.82 | BRD4 (0.64) | — | |
| SCHEMBL30009525 | 0.82 | IKBKB (0.76) | CITIKBKBCHUK | |
| SCHEMBL30008979 | 0.81 | CIT (0.59) | CITIKBKBCHUKKITJAK1 | |
| SCHEMBL30009873 | 0.81 | JAK1 (0.60) | CITIKBKBCHUKKITJAK1 | |
| SCHEMBL30010036 | 0.80 | JAK1 (0.58) | NUDT1IKBKBCHUKJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | CIT 417/4885NUDT1 3177/4885IKBKB 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.